Evaluation of candidemia risk factors and Candida species distribution in intensive care units among patients with and without COVID-19

References

1. 1.↵
   1. Tanrıverdi SE,
   2. Yakupoğulları Y,
   3. Otlu B

   . Diagnosis of COVID-19: serological and molecular tests. [Updated 2020; accessed 2024 Jan 26]. Available from: https://dergipark.org.tr/tr/pub/aktd/issue/58233/841123
2. 2.↵
   1. Baloch S,
   2. Baloch MA,
   3. Zheng T,
   4. Pei X

   . The coronavirus disease 2019 (COVID-19) Pandemic. Tohoku J Exp Med 2020; 250: 271–278.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Arastehfar A,
   2. Carvalho A,
   3. Nguyen MH,
   4. Hedayati MT,
   5. Netea MG,
   6. Perlin DS, et al.

   COVID-19-associated Candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J Fungi (Basel) 2020; 6: 211.

   OpenUrl
4. 4.↵
   1. Yang W,
   2. Cao Q,
   3. Qin L,
   4. Wang X,
   5. Cheng Z,
   6. Pan A, et al.

   Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020; 80: 388–393.

   OpenUrlPubMed
5. 5.↵
   1. Dasgupta S,
   2. Das S,
   3. Chawan NS,
   4. Hazra A

   . Nosocomial infections in the intensive care unit: incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J Crit Care Med 2015; 19: 14–20.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Bouza E,
   2. Muñoz P

   . Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32: S87–S91.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.
   1. Meric M,
   2. Willke A,
   3. Caglayan C,
   4. Toker K

   . Intensive care unit-acquired infections: incidence, risk factors and associated mortality in a Turkish university hospital. Jpn J Infect Dis 2005; 58: 297–302.

   OpenUrlPubMed
8. 8.
   1. Büke Ç,
   2. Sipahi OR,
   3. Taşbakan M,
   4. Yamazhan T,
   5. Arda B,
   6. Özinel MA, et al.

   Evaluation of infections developed in internal medicine intensive care unit. Infection 2005; 19: 67–73.

   OpenUrl
9. 9.↵
   1. Çetin ES,
   2. Kaya S,
   3. Pakbaş İ,
   4. Demirci M

   . Microorganisms isolated from patients in intensive care units and their antibiotic susceptibilities. Inonu Uni Med J 2007; 14: 69–73.

   OpenUrl
10. 10.
    1. Erbay H,
    2. Yalcin AN,
    3. Serin S,
    4. Turgut H,
    5. Tomatir E,
    6. Cetin B, et al.

    Nosocomial infections in intensive care unit in a Turkish university hospital: a 2-year survey. Intensive Care Med 2003; 29: 1482–1488.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Song G,
    2. Liang G,
    3. Liu W

    . Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185: 599–606.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Pristov KE,
    2. Ghannoum MA

    . Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect 2019; 25: 792–798.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Vena A,
    2. Bouza E,
    3. Valerio M,
    4. Padilla B,
    5. Paño-Pardo JR,
    6. Fernández-Ruiz M, et al.

    Candidemia in non-ICU surgical wards: comparison with medical wards. PLoS One 2017; 12: e0185339.

    OpenUrlCrossRef
14. 14.↵
    1. Tukenmez Tigen E,
    2. Bilgin H,
    3. Perk Gurun H,
    4. Dogru A,
    5. Ozben B,
    6. Cerikcioglu N, et al.

    Risk factors, characteristics, and outcomes of candidemia in an adult intensive care unit in Turkey. Am J Infect Control 2017; 45: e61–e63.

    OpenUrl
15. 15.↵
    1. Yenigün Koçak B,
    2. Kuloğlu F,
    3. Doğan Çelik A,
    4. Akata F

    . [Evaluation of epidemiological characteristics and risk factors of candidemia in adult patients in a tertiary-care hospital]. Mikrobiyol Bul 2011; 45: 489–503. [In Turkish].

    OpenUrlPubMed
16. 16.↵
    1. Gültekin B,
    2. Eyigör M,
    3. Telli M,
    4. Aksoy M,
    5. Aydın N

    . Retrospective analysis of Candida species isolated from blood cultures over a 7-year period. Ankem 2010; 24: 202–208.

    OpenUrl
17. 17.↵
    1. Öztürk T,
    2. Özseven AG,
    3. Çetin ES,
    4. Kaya S

    . Typing of Candida isolates from blood cultures and investigation of antifungal susceptibilities. Kocatepe Tıp Dergisi 2013; 14: 17–22.

    OpenUrl
18. 18.↵
    1. Yang SP,
    2. Chen YY,
    3. Hsu HS,
    4. Wang FD,
    5. Chen LY,
    6. Fung CP

    . A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. BMC Infect Dis 2013; 13: 10.

    OpenUrlCrossRef
19. 19.↵
    1. Sasso M,
    2. Roger C,
    3. Sasso M,
    4. Poujol H,
    5. Barbar S,
    6. Lefrant JY, et al.

    Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: a 10-year study. Mycoses 2017; 60: 770–780.

    OpenUrlCrossRef
20. 20.↵
    1. Segrelles-Calvo G,
    2. de S Araújo GR,
    3. Llopis-Pastor E,
    4. Carrillo J,
    5. Hernández-Hernández M,
    6. Rey L, et al.

    Candida spp. co-infection in COVID-19 patients with severe pneumonia: prevalence study and associated risk factors. Respir Med 2021; 188: 106619.

    OpenUrl
21. 21.↵
    1. Alexander BD,
    2. Johnson MD,
    3. Pfeiffer CD,
    4. Jiménez-Ortigosa C,
    5. Catania J,
    6. Booker R, et al.

    Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56: 1724–1732.

    OpenUrlCrossRefPubMed
22. 22.↵
    National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470–485.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Çalık Ş,
    2. Tosun S,
    3. Altın Ü,
    4. Arı A,
    5. Olut AI,
    6. Yüksel Ergin Ö

    . Is there any clinical significance of coagulase-negative Staphylococci isolated from blood cultures? Flora 2017; 22: 34–41.

    OpenUrl
24. 24.↵
    1. Altınbaş R,
    2. Yağmuroğlu A,
    3. Çetin E,
    4. Çaprak S,
    5. Türkay S,
    6. Karkaç E, et al.

    Co-infections and antimicrobial resistance in COVID-19 diagnosed patients. Eskisehir Med J 2023; 4: 95–101.

    OpenUrl
25. 25.
    1. Aytaç Ö,
    2. Şenol FF,
    3. Şenol A,
    4. Öner P,
    5. Aşçı Toraman Z

    . Comparison of the species distribution and antibiotic susceptibility profiles of blood culture isolates from intensive care unit patients before and during COVID-19 pandemic. Turk Mikrobiyol Cemiy Derg 2022; 52: 39–47.

    OpenUrl
26. 26.↵
    1. Yiğit N,
    2. Aktaş AE,
    3. Doğruman Al F,
    4. Ayyildiz A

    . Typing and methicillin resistance of Coagulase-negative Staphylococci isolated from blood cultures. Turk Hij Den Biyol Derg 2008; 65: 61–66.

    OpenUrl
27. 27.
    National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470–485.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Asaad AM,
    2. Ansar Qureshi M,
    3. Mujeeb Hasan S

    . Clinical significance of coagulase-negative Staphylococci isolates from nosocomial bloodstream infections. Infect Dis (Lond) 2016; 48: 356–360.

    OpenUrl
29. 29.↵
    1. Becker K,
    2. Heilmann C,
    3. Peters G

    . Coagulase-negative Staphylococci. Clin Microbiol Rev 2014; 27: 870–926.

    OpenUrlAbstract/FREE Full Text
30. 30.
    1. Von Eiff C,
    2. Peters G,
    3. Heilmann C

    . Pathogenesis of infections due to coagulase-negative Staphylococci. Lancet Infect Dis 2002; 2: 677–685.

    OpenUrlCrossRefPubMedWeb of Science